ReviewViruses2019
H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Review in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 56 citations in OpenAlex.
- Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes.Molecular therapy. Oncology · 2026Article
- Tuning epigenetics to enhance cancer virotherapy.Acta pharmaceutica Sinica. B · 2026Review
- Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory.Cell reports. Medicine · 2026Article
- Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702).International journal of clinical oncology · 2026Review
- Therapeutic potential of oncolytic viruses in hematopoietic malignancies: from preclinical insights to clinical realities.Frontiers in microbiology · 2026Review
- Design and Efficacy of Oncolytic Viruses and Antitumor Vaccines: A Dead End in the Immunotherapy of Pancreatic Cancer?International journal of molecular sciences · 2025Review
- Review
- Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer's defenses.Frontiers in immunology · 2025Review
- Parvoviruses NS1 oncolytic attributes: mechanistic insights and synergistic anti-tumor therapeutic strategies.Frontiers in microbiology · 2025Review
- Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice.Biomedicines · 2024Article
- Article
- Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.EBioMedicine · 2024Article
- Intracellular delivery of oncolytic viruses with engineered Salmonella causes viral replication and cell death.iScience · 2024Article
- The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics.Pathogens (Basel, Switzerland) · 2024Review
- Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma.International journal of molecular sciences · 2024Review
- New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.Frontiers in immunology · 2024Review
- Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.Human gene therapy · 2023Review
- Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application.Applied microbiology and biotechnology · 2023Article
- Epigenetic Rewiring of Metastatic Cancer to the Brain: Focus on Lung and Colon Cancers.Cancers · 2023Article
- Design and Characterization of Mutated Variants of the Oncotoxic Parvoviral Protein NS1.Viruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rat protoparvovirus H-1PV is nonpathogenic in humans, replicates preferentially in cancer cells, and has natural oncolytic and oncosuppressive activities. The virus is able to kill cancer cells by activating several cell death pathways. H-1PV-mediated cancer cell death is often immunogenic and triggers anticancer immune responses. The safety and tolerability of H-1PV treatment has been demonstrated in early clinical studies in glioma and pancreatic carcinoma patients. Virus treatment was associated with surrogate signs of efficacy including immune conversion of tumor microenvironment, effective virus distribution into the tumor bed even after systemic administration, and improved patient overall survival compared with historical control. However, monotherapeutic use of the virus was unable to eradicate tumors. Thus, further studies are needed to improve H-1PV's anticancer profile. In this review, we describe H-1PV's anticancer properties and discuss recent efforts to improve the efficacy of H-1PV and, thereby, the clinical outcome of H-1PV-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.